Panacea Biotec Ltd

₹ 142 2.79%

24 Apr 4:11 p.m.

panaceabiotec.com BSE: 531349 NSE : PANACEABIO

About

Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited and was publicly listed in the year 1995. Panacea Biotec is a research based Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals, Vaccines and Biosimilars.

Key Points

Business Highlights^[1]
a. Being WHO-prequalified, the Company is one of the leading supplier of vaccines to Government of India, UNICEF & PAHO^ since more than two decades.
b. One of the leading domestic pharmaceutical formulations player with brands in super specialty and chronic care segments - Organ Transplantation, Oncology and Diabetes
c. 3 ANDAs approved by USFDA, 6 ANDAs submitted and awaiting approval from USFDA
d. 34 Active Patents globally and 21 Patent applications under process
e. Total 74 Brands of which 70 are for Pharma and 4 for Vaccines
f. 11 brands in domestic markets of which Pharma – 10; Vaccine – 1

Website BSE NSE

Market Cap ₹ 868 Cr.
Current Price ₹ 142
High / Low ₹ 202 / 114
Stock P/E
Book Value ₹ 53.9
Dividend Yield 0.00 %
ROCE -12.5 %
ROE -25.1 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter
Debtor days have improved from 30.4 to 17.4 days.

Cons

Stock is trading at 2.68 times its book value
Company has low interest coverage ratio.
Company has a low return on equity of -13.5% over last 3 years.
Contingent liabilities of Rs.640 Cr.
Earnings include an other income of Rs.18.8 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
	69.02	79.86	36.26	119.26	38.48	41.50	61.34	48.74	71.97	75.02	89.41	94.59	95.23
	65.75	95.97	55.67	136.71	54.92	60.88	133.36	55.06	59.68	71.59	82.60	84.63	88.59
Operating Profit	3.27	-16.11	-19.41	-17.45	-16.44	-19.38	-72.02	-6.32	12.29	3.43	6.81	9.96	6.64
OPM %	4.74%	-20.17%	-53.53%	-14.63%	-42.72%	-46.70%	-117.41%	-12.97%	17.08%	4.57%	7.62%	10.53%	6.97%
	7.17	7.75	4.15	3.47	2.38	2.57	6.53	7.92	9.71	10.27	3.34	2.13	3.05
Interest	1.89	1.86	1.78	1.91	1.91	1.44	2.47	2.21	2.68	2.70	3.46	3.55	3.41
Depreciation	6.64	6.57	6.43	6.48	6.46	7.06	6.28	6.24	6.08	5.90	5.40	5.34	5.21
Profit before tax	1.91	-16.79	-23.47	-22.37	-22.43	-25.31	-74.24	-6.85	13.24	5.10	1.29	3.20	1.07
Tax %	0.52%	-9.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	486.08%	0.00%	0.00%	59.81%
	1.90	-18.31	-23.47	-22.37	-22.43	-25.31	-74.24	-6.85	13.24	-19.69	1.29	3.20	0.43
EPS in Rs	0.31	-2.99	-3.83	-3.65	-3.66	-4.13	-12.11	-1.12	2.16	-3.21	0.21	0.52	0.07
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
	701	596	498	679	647	530	184	96	158	344	236	257	354
	771	653	586	612	534	460	192	243	248	343	308	320	327
Operating Profit	-71	-57	-88	68	113	70	-8	-147	-90	0	-73	-63	27
OPM %	-10%	-10%	-18%	10%	17%	13%	-4%	-152%	-57%	0%	-31%	-24%	8%
	-16	-5	304	28	75	16	84	322	-14	21	13	34	19
Interest	101	106	148	93	115	104	103	105	5	8	7	10	13
Depreciation	75	84	69	66	71	66	34	33	27	27	26	24	22
Profit before tax	-263	-251	-0	-63	1	-84	-61	37	-136	-13	-94	-63	11
Tax %	21%	8%	0%	-3%	38%	14%	-17%	29%	-13%	-12%	0%	-40%
	-208	-230	-0	-65	1	-73	-72	27	-153	-14	-94	-88	-15
EPS in Rs	-33.90	-37.54	-0.07	-10.64	0.14	-11.85	-11.73	4.33	-24.97	-2.36	-15.27	-14.28	-2.41
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-8%
5 Years:	7%
3 Years:	18%
TTM:	58%

Compounded Profit Growth
10 Years:	5%
5 Years:	-7%
3 Years:	7%
TTM:	84%

Stock Price CAGR
10 Years:	-1%
5 Years:	-5%
3 Years:	-27%
1 Year:	15%

Return on Equity
10 Years:	-22%
5 Years:	-24%
3 Years:	-13%
Last Year:	-25%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	6	6	6	6	6	6	6	6	6	6	6	6	6
Reserves	808	555	556	517	518	450	382	412	855	502	409	320	324
Preference Capital	0	0	0	16	16	0	9	0	0	0	0	0
	867	922	990	1,015	1,019	1,023	960	689	67	65	84	102	138
	172	197	334	341	265	303	325	335	211	217	263	296	305
Total Liabilities	1,853	1,680	1,886	1,879	1,807	1,782	1,673	1,442	1,138	790	762	724	772
	1,001	959	1,086	1,060	988	942	891	496	499	464	454	435	454
CWIP	47	28	26	17	19	28	37	3	4	13	1	28	47
Investments	258	272	394	395	395	345	345	3	3	0	0	0	0
	546	422	380	408	406	467	401	940	633	313	307	260	271
Total Assets	1,853	1,680	1,886	1,879	1,807	1,782	1,673	1,442	1,138	790	762	724	772

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
	253	-39	53	45	98	104	172	107	-83	38	-53	-11
	-119	-14	-18	-29	23	-18	-3	-10	-17	-37	40	2
	-161	55	-38	-11	-129	-91	-164	-98	109	-7	10	9
Net Cash Flow	-28	1	-3	5	-8	-5	6	-2	10	-6	-3	1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	35	42	66	54	80	121	283	96	41	37	36	17
Inventory Days	357	316	310	178	233	304	618	203	619	180	421	260
Days Payable	124	216	397	236	295	490	1,002	373	847	257	472	289
Cash Conversion Cycle	268	141	-20	-4	17	-65	-102	-74	-188	-39	-15	-12
Working Capital Days	87	65	-143	-57	43	18	-297	215	900	8	-63	-138
ROCE %	-9%	-9%	-9%	2%	4%	4%	3%	-14%	-8%	-1%	-16%	-13%

Shareholding Pattern

Numbers in percentages

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%
	0.03%	0.02%	0.00%	0.00%	0.00%	0.14%	0.18%	0.18%	0.22%	0.26%	0.26%	0.27%
	0.42%	0.40%	0.13%	0.00%	0.00%	0.29%	0.43%	0.43%	0.54%	0.57%	0.69%	0.84%
	25.95%	25.99%	26.28%	26.41%	26.41%	25.98%	25.81%	25.80%	25.66%	25.58%	25.46%	25.30%
No. of Shareholders	54,313	52,816	52,465	49,563	49,896	49,078	50,533	48,634	47,815	48,878	47,091	46,242

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	74.60%	74.07%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%
	0.00%	0.00%	0.23%	0.00%	0.10%	0.00%	0.18%	0.27%
	0.04%	0.12%	1.23%	1.61%	1.27%	0.00%	0.43%	0.84%
	25.36%	25.81%	24.95%	24.79%	25.04%	26.41%	25.80%	25.30%
No. of Shareholders	9,888	10,246	10,642	10,582	27,228	49,563	48,634	46,242

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Panacea Biotec Ltd

Panacea Biotec Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls